All In Biotech

NDA 017011 · Abbvie

Pred Forte

Prednisolone Acetate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Jun 6, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1973

May 30, 1973

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,078

579 Phase 3, 236 recruiting

FAERS reports

11,227

5,507 serious, 577 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 3, 2026.

INDICATIONS AND USAGE Prednisolone acetate ophthalmic suspension 1% is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 30, 1973 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • PRED FORTE · PREDNISOLONE ACETATE 1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Prednisolone" as an intervention, any sponsor and status, largest first.

All 2,078 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure1,267
  • drug ineffective945
  • eye pain791
  • recalled product administered764
  • off label use735
  • no adverse event677
  • eye irritation471
  • vision blurred465
  • headache382
  • fatigue379
  • ocular hyperaemia336
  • diarrhoea301

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200437
200571
200694
2007109
2008168
2009111
2010171
2011148
2012279
2013200
2014268
2015405
2016649
2017439
2018527
2019604
20201,786
2021562
2022683
2023757
2024819
2025933
20261,407

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pred Forte (Prednisolone Acetate)

2024 spending

$959K

Beneficiaries

1,718

3,969 claims

Per beneficiary

$558

$29.17 per unit

View as table
YearSpending
2020$1,558,557
2021$1,365,453
2022$1,264,613
2023$1,189,393
2024$959,454

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,679 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.